GPC2-Targeting CAR Architecture for Native Antigen Recognition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for the development of novel immunotherapies targeting Glypican 2 (GPC2) antigen for the treatment of various cancers, as existing CAR-T cell technologies may not effectively recognize and kill cancer cells expressing native levels of GPC2 without MHC presentation.
Innovation Solution
Development of chimeric antigen receptors (CARs) comprising an anti-GPC2 single-chain variable fragment (scFv), a transmembrane domain (TMD), and an intracellular signaling domain (ICD), optimized with specific CDR sequences and hinge/spacer domains, to enhance recognition and killing of GPC2-expressing cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapies are used, then treatment of common cancers is provided, but effective recognition and treatment of GPC2-expressing malignancies is inadequate
Solution Approach 1:
The patent modifies the immunotherapy approach by changing the target parameter from conventional cancer markers to GPC2 antigen, creating CAR T-cells with specific affinity for GPC2-expressing malignancies while maintaining effectiveness against common cancers
Solution Approach 2:
The developed CAR T-cell therapy demonstrates multi-functionality by effectively targeting both common cancers and GPC2-expressing malignancies, providing a universal treatment approach that addresses multiple cancer types through the common GPC2 antigen target
2Reliability
If CAR T-cell therapy is developed to target GPC2, then binding affinity and efficacy are enhanced, but the complexity of the immunotherapy approach increases
Solution Approach 1:
The CAR T-cell receptor is segmented into distinct functional domains including the GPC2-targeting scFv region, transmembrane domain, and intracellular signaling domain, allowing each component to be optimized independently while maintaining overall efficacy
Solution Approach 2:
The patent introduces GPC2 as an intermediary target antigen that mediates the interaction between CAR T-cells and cancer cells, providing a specific binding interface that enhances affinity without requiring direct T-cell recognition of complex tumor antigens
Data Source
AI summary
The present disclosure generally relates to, inter alia, antibodies and chimeric antigen receptors (CARs) that bind a Glypican 2 (GPC2) antigen. The disclosure also provides compositions and methods useful for producing such antibodies and CARs, as well as methods for the diagnosis, prevention, and/or treatment of health conditions associated with the GPC2 antigen expression.